New ETF Book by Larry Connors - Click here to read more
Brussels (Belgium), 8 May 2009 - 06:00 PM (CEST) - UCB is seeking to acquire the Schwarz Pharma shares held by minority shareholders - representing approximately 0.4% of stock capital - by way of a so-called "squeeze-out" procedure. In accordance with the legally stipulated procedure (under Sections 327a ff. of the German Stock Corporation Act [AktG]), the Schwarz Pharma shares held by minority shareholders are to be transferred to UCB and in return for an appropriate cash compensation, by way of a resolution still to be passed by the Annual General Meeting of Schwarz Pharma AG.
UCB SP GmbH, Monheim, as the principal shareholder of Schwarz Pharma, informed the Executive Board of Schwarz Pharma AG in a letter of today's date that it had set the cash compensation for the transfer of the shares held by minority shareholders in Schwarz Pharma to UCB SP GmbH, as the principal shareholder, to EUR 111.44 per share. The cash compensation amount was determined with the expert support provided by the chartered accountants Ernst & Young AG Wirtschaftsprufungsgesellschaft Steuerberatungsgesellschaft, Duesseldorf/Germany.
The cash compensation amount corresponds to the volume-weighted average Schwarz Pharma stock market price measured over the last three months prior to publication of the squeeze-out request by Schwarz Pharma on 6 February, 2009.
The squeeze-out resolution will be considered at the Annual General Meeting of Schwarz Pharma AG, scheduled for July 8, 2009. To be legally effective, this resolution must be registered in the German Commercial Register (Handelsregister) at the seat of Schwarz Pharma AG. Once the resolution is legally effective, all shares held by minority shareholders will be transferred to UCB in return for payment of the appropriate cash compensation. All trading of Schwarz Pharma shares on the stock exchange shall then be terminated.
About UCB UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing approximately 10 000 people in over 40 countries, UCB generated revenue of EUR 3.6 billion in 2008. UCB is listed on Euronext Brussels (symbol: UCB).
About Schwarz Pharma Schwarz Pharma AG (Monheim, Germany; www.schwarzpharma.com) is a member of the UCB group of companies. UCB holds 99.6% of the Schwarz Pharma shares.
For further information Antje Witte, Corporate Communications & Investor Relations, UCB T +49-2173-48-1866, antje.witte@ucb.com
Nancy Nackaerts, External Communications, UCB T +32 2 559 9264, nancy.nackaerts@ucb.com
Forward-looking statements This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.
For the pdf-version of this press release, please click on the link below:
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
SOURCE: UCB
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
